bis(1-methylindol-3-yl)-(1,1'-biphenyl-4-yl)methane | 347376-80-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis(1-methylindol-3-yl)-(1,1'-biphenyl-4-yl)methane
• 英文别名: 1-methyl-3-[(1-methylindol-3-yl)-(4-phenylphenyl)methyl]indole
• CAS: 347376-80-1
• 化学式: C₃₁H₂₆N₂
• 分子量: 426.561
• InChiKey: FENAGUKIQAZTLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  9.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  1-甲基吲哚 、 对苯基苯甲醛 在 N-溴代丁二酰亚胺(NBS) 作用下， 反应 1.0h， 以88%的产率得到bis(1-methylindol-3-yl)-(1,1'-biphenyl-4-yl)methane
  参考文献：
  名称：

  N-溴琥珀酰亚胺在无溶剂条件下催化吲哚与羰基化合物的缩合反应

  摘要：

  人们发现，在没有溶剂的情况下，NBS是吲哚与醛或酮缩合的有效催化剂。

  DOI：

  10.1002/jhet.5570390539

文献信息

• Bis-heteroaryl alkanes as therapeutic agents
  申请人：Mjalli M.M. Adnan

  公开号：US20060128784A1

  公开（公告）日：2006-06-15

  This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

  本发明提供了一些化合物，这些化合物可用作蛋白酪氨酸磷酸酶（PTPase）的抑制剂。作为PTPase的抑制剂，本发明的化合物可用于管理、治疗、控制和辅助治疗哺乳动物中由PTPase活性介导的疾病。这些疾病包括I型糖尿病、II型糖尿病、免疫功能障碍、艾滋病、自身免疫性疾病、葡萄糖不耐受、肥胖症、癌症、牛皮癣、过敏性疾病、传染性疾病、炎症性疾病、涉及生长激素或影响生长激素产生的生长因子或细胞因子调节合成的疾病，以及阿尔茨海默病。
• Bis-Heteroaryl alkanes as therapeutic agents
  申请人：——

  公开号：US20030130335A1

  公开（公告）日：2003-07-10

  This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

  这项发明提供了一种化合物，可用作蛋白酪氨酸磷酸酶（PTPases）的抑制剂。作为PTPases的抑制剂，本发明的化合物对于治疗哺乳动物中由PTPase活性介导的疾病的管理、治疗、控制和辅助治疗非常有用。这些疾病包括I型糖尿病、II型糖尿病、免疫功能障碍、艾滋病、自身免疫病、葡萄糖不耐受、肥胖症、癌症、银屑病、过敏性疾病、传染性疾病、炎症性疾病、涉及生长激素调节合成或影响生长激素、生长因子或细胞因子的产生的疾病，以及阿尔茨海默病。
• BIS-HETEROARYL ALKANES AS THERAPEUTIC AGENTS
  申请人：Transtech Pharma

  公开号：EP1438044A1

  公开（公告）日：2004-07-21
• US7022730B2
  申请人：——

  公开号：US7022730B2

  公开（公告）日：2006-04-04
• [EN] BIS-HETEROARYL ALKANES AS THERAPEUTIC AGENTS<br/>[FR] BIS-HETEROARYL ALCANES UTILISES COMME AGENTS THERAPEUTIQUES
  申请人：TRANSTECH PHARMA INC

  公开号：WO2003032982A1

  公开（公告）日：2003-04-24

  This invention provides compounds (I) which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease. Wherein R1 and R2 independently comprise (a) or (b).